Interest in Pre-exposure Prophylaxis (PrEP) for HIV is Limited Among Women in a General Obstetrics & Gynecology Setting
- 156 Downloads
Pre-exposure prophylaxis (PrEP) is an important tool for reducing the risk of HIV acquisition, but identifying eligible and interested female patients remains difficult. We collected 144 surveys at urban Obstetrics & Gynecology clinics in Louisiana to assess interest in PrEP. Study participants were predominantly African–American (61.8%) and 45.1% had incomes of less than $20,000 per year. 84.7% of participants estimated their risk of HIV acquisition to be low. Initial interest in PrEP was moderate at 37.5% of the population. Number of partners, condom use, and self-perceived risk of HIV acquisition were associated with initial interest. After receiving more information about side effects and compliance requirements, only four of 144 (7.8% of initially interested, 2.8% of total) women remained interested in using PrEP. Concern about side effects was the major barrier to persistent interest. Further study is needed to determine how best to identify PrEP candidates in Obstetrics & Gynecology settings.
KeywordsPre-exposure prophylaxis HIV infections Surveys and questionnaires Ambulatory care facilities
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in this study were in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.Centers for Disease Control and Prevention. HIV Surveillance Report, 2017; vol. 29. Published November 2018. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 9 Jan 2019.
- 2.Centers for Disease Control and Prevention. HIV among women. Available from: https://www.cdc.gov/hiv/group/gender/women/index.html. Accessed 5 Dec 2018.
- 3.AIDSVu. Mapping PrEP: First Ever Data on PrEP Users Across the U.S. Available from: https://aidsvu.org/prep/. Accessed 4 Jan 2019.
- 4.Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018.
- 13.Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214(1):55–64.CrossRefGoogle Scholar
- 19.McMahan V, Martin A, Garske L, Baeten J, Banta-Green C, Stekler J. Knowledge about PrEP among MSM and Trans Methamphetamine Users in Seattle. Conference on Retroviruses and Opportunistic Infections 2017, Abstract # 967. Available at: http://www.croiconference.org/sessions/knowledge-about-prep-among-msm-and-trans-methamphetamine-users-seattle. Accessed 10 Jan 2019.
- 21.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 11 Jan 2019.
- 25.Preexposure prophylaxis for the prevention of human immunodeficiency virus. Committee Opinion No. 595. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:1133–6.Google Scholar